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Abstract
Purpose Paracetamol is one of the world’s most commonly
used drugs. In overdose, it is well established to be hepatotox-
ic. The aim of this review was to identify factors that have
been, or actually are, associated with the development of liver
injury after paracetamol exposure in humans.
Method Google Scholar and PubMed were searched on vari-
ous dates between December 2016 and March 2017. Papers
identified had their references analysed for further studies that
might be relevant.
Results At the time of writing, there was little good quality
clinical evidence—from studies of paracetamol overdose or
therapeutic use—to suggest that any groups of people are
relatively protected from, or are at greater risk of, liver injury.
The factors that were historically used to indicate higher risk
in the UK have no good quality clinical evidence to support
their re-introduction into clinical practice. The safe (and still
effective) oral dose of paracetamol in patients weighing less
than 50 kg has not been established.
Conclusion There is no patient group that is unequivocally at
elevated risk of paracetamol-induced liver toxicity. We pro-
pose two clinical scenarios that warrant further research.
Firstly, there is a need to establish whether the dose of para-
cetamol should be reduced in patients with low body weight.
Secondly, if or when genomic information regarding individ-
ual patients becomes readily available to inform prescribing,
we propose the contribution of the genome to paracetamol
toxicity should be re-investigated with robustly designed stud-
ies. Such studies could enhance the safe use of one of the most
frequently taken drugs.
Keywords Paracetamol . Acetaminophen . Hepatotoxicity .
Genomics . DILI
Introduction
Paracetamol
Paracetamol (acetaminophen, APAP) is an analgesic for mild
to moderate pain and an anti-pyretic [1]. It is widely available
for purchase without prescription and in recommended dos-
ages is believed to have an excellent safety profile [1].
However, in overdose, paracetamol is well known to be hep-
atotoxic [2]. Fortunately, the toxicity of paracetamol overdose
is effectively attenuated by administration of the antidote
acetylcysteine (NAC), at least if administered within 8 h of
the overdose [3].
In this review, we will discuss factors that have been, or
actually are, associated with the development of liver injury
following paracetamol exposure. Our objective is to critically
identify genotypes and phenotypes that put patients at higher
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or lower risk of toxicity. In this review, we define acute liver
injury as having serum alanine aminotransferase activity
(ALT) of 100–1000 IU/L and hepatotoxic i ty as
ALT > 1000 IU/L.
Epidemiology of overdose
Paracetamol poisoning is an important clinical entity as it
accounts for 50% of poisonings in the UK and 10% in the
USA [4, 5]. In the UK alone, it results in 82,000–90,000
hospital presentations per year [2]. Toxicity generally falls into
two categories: intentional overdose and unintentional over-
dose (therapeutic misadventure). There are reports of rare
cases of toxicity following dosing within the therapeutic
range, although there is debate about whether this latter cate-
gory truly exists. Indeed a review article concluded that in
prospective trials, therapeutic doses of paracetamol do not
cause toxicity, and notes that only in retrospective studies does
therapeutic toxicity occur and this is likely due to the biases
inherent in retrospective analysis [2, 6, 7]. Around 150–250
deaths occur directly due to paracetamol poisoning each year
in the UK and these generally occur in patients who presented
late to hospital, took a massive overdose, those who staggered
their overdose, or who took an unintentional overdose [8, 9].
Since 2012, new guidelines on the treatment of paracetamol
poisoning have been implemented in the UK [10]. The revised
guidelines recommend treating all patients with a paracetamol
concentration above a single treatment line on the paracetamol
nomogram (the ‘100 milligram (mg) per litre (L) at four hours
after overdose treatment line’) and treating all patients with a
staggered overdose or uncertain time of ingestion [10]. This
has been reported to have resulted in a 7% absolute increase in
the number of patients admitted to hospital for paracetamol
poisoning [2].
Paracetamol metabolism and toxicity
Following oral administration absorption is rapid, with a
paracetamol peak plasma concentration (Cmax) occurring
at ~ 1 h post-administration. However, absorption may be
prolonged in a patient taking an overdose [11, 12]. The
mean systemic bioavailability of paracetamol following
oral administration is ~ 75% [13, 14]. Following delivery
of a therapeutic dose of paracetamol to a healthy person,
the majority of paracetamol is directly conjugated in the
liver by phase II enzymes to form glucuronide (APAP-
glu) and sulphate (APAP-sul) derivatives. Early pharma-
cokinetic studies demonstrated that following a therapeu-
tic paracetamol dose, 55% is excreted as the glucuronide,
30% as the sulphate and 4% is excreted as the products of
oxidative metabolism. The metabolic half-life (t1/2) is 1.5–
2.5 h but may be prolonged following paracetamol over-
dose [13]. The sulphation pathway is saturable at
therapeutic doses whereas the glucuronidation pathway
only becomes saturated in overdoses (see Fig. 1 for a
summary of the major pathways of paracetamol metabo-
lism) [15, 16].
A smaller proportion is oxidised by phase I reactions
catalysed by mixed function oxidases (cytochrome P450,
CYP450), nicotinamide adenine dinucleotide phosphate
oxidase and oxygen [13, 17]. These phase I oxidative
reactions metabolise 2–10% of paracetamol to a reactive
intermediate, N-acetyl-p-benzoquinone imine (NAPQI)
which mediates the hepatotoxic effect of paracetamol.
The proportion of the dose metabolised by this pathway
increases in overdose and, potentially, in the presence of
other pathological/physiological states [13, 18–20]. In
humans, the CYP450 enzyme that predominately cataly-
ses the formation of NAPQI is CYP2E1, although in vitro
CYP3A4, CYP2D6 and CYP1A2 have also been impli-
cated in the formation of the toxic metabolite [18–20].
NAPQI is a strong oxidising agent and has the potential
to cause liver and kidney damage by reacting with cellular
and mitochondrial proteins [21]. However, following ther-
apeutic doses, a healthy liver is able to detoxify NAPQI
rapidly due to the presence of reduced glutathione (GSH).
The sulfhydryl group of GSH binds NAPQI, which is
subsequently excreted in the urine as mercapturic acid or
cysteine conjugates [13, 20]. This leads to depletion of
hepatocyte GSH [13]. In paracetamol overdose, a greater
proportion of the dose is shunted to the oxidative pathway
which results in greater NAPQI formation [13]. When
large quantities of NAPQI are formed, hepatocyte gluta-
thione can be critically depleted, meaning that excess
NAPQI is not detoxified and cell injury occurs [13].
NAPQI formation can be monitored indirectly through
the presence of circulating paracetamol-protein adducts
(PPA). There is evidence to suggest that PPA are formed
in healthy individuals at therapeutic doses, particularly
following repeated doses, suggesting that not all NAPQI
is scavenged by glutathione even during therapeutic ad-
ministration (see Fig. 1 for a summary of the major
pathways of paracetamol metabolism) [22, 23].
It is widely assumed that paracetamol doses in the thera-
peutic range are not toxic. However, a 145-patient randomised
controlled trial (RCT) reported that 4 g of paracetamol daily in
divided doses for 4 days was associated with an increase in
ALTactivity in a significant proportion of patients when com-
pared to placebo, although the clinical significance of this
elevation in ALT is unclear [24]. The patients in this trial were
admitted to a trials unit with a possible change in their sleep
patterns and diet that could have caused fluctuations in ALT.
However, another 205-patient RCT reported that, although a
minority of patients did experience an ALT rise with 4 g para-
cetamol daily, this rise resolved following further days of dos-
ing [25]. Therefore, there is conflicting evidence regarding the
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effect of therapeutic doses of paracetamol on liver enzymes
and the significance of an increase in ALT activity.
A retrospective analysis of 9479 referrals to multi-
national liver transplant units gave an event rate of 3.3
million treatment years for non-overdose paracetamol as
the aetiology for acute liver failure requiring transplant.
However, cases were assigned as ‘non-overdose’ by an
expert committee if there was no history of overdose
and a non-toxic plasma paracetamol concentration
(PPC), meaning that some of these cases may in fact have
been concealed overdoses if a history of overdose was not
given and enough time had elapsed for PPC to become
undetectable [26].
In summary, the risk of clinically significant liver inju-
ry at therapeutic doses of paracetamol is very low. Despite
this, in this review, we consider evidence from both ther-
apeutic dosing and overdose studies because pre-clinical
data suggest everyone would develop liver injury if the
dose of paracetamol was sufficiently high for that individ-
ual. Therefore, a key question is whether certain individ-
uals have an ‘inflection point’ for clinically important
paracetamol toxicity at a dose within or close to the rec-
ommended therapeutic dose. The dose-response relation-
ship of paracetamol and liver injury is in contrast to so-
called idiosyncratic drug-induced liver injury, which is
restricted to a subset of susceptible individuals.
Method
Literature search strategy
Google Scholar and PubMed were searched on various dates
between December 2016 and March 2017, ending on 15th
March 2017 using the following terms, and variants thereof,
and all articles discovered were considered for inclusion:
(paracetamol OR acetaminophen hepatotoxicity) AND genet-
ic differences/polymorphisms OR children/neonates/young
people/paediatric OR older people/elderly/geriatric OR nutri-
tional state/malnutrition OR body weight/low body weight
OR alcohol/alcohol-dependence OR drug interactions/
potentiation OR liver disease/chronic liver disease/liver
failure.
Furthermore, papers identified had their references
analysed for any further studies that might be relevant to this
review.
Inclusion criteria
1. Studies with human participants and studies involving
actual human tissue samples where liver injury or
hepatotoxicity is detailed, including mechanistic stud-
ies, case series, observational studies and randomised
Fig. 1 Major pathways of paracetamol metabolism
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controlled trials, reviews, and systematic review
articles
Exclusion criteria
1. Studies involving animals
2. Studies not published in the English language
3. Studies where it was not possible to ascertain from the
title or abstract that the inclusion criteria were met
4. Studies already included in other published reviews where
the review is cited in the text
Results—are some people at higher risk
of paracetamol toxicity?
Genetic differences
A number of enzymes are involved in the metabolism of para-
cetamol. Variations in some of these may contribute directly or
indirectly to increase an individual’s risk of toxicity and may
account for the wide inter-individual variability of paraceta-
mol metabolism reported in some studies [17, 20, 27].
Although investigations have been undertaken looking at en-
zymes in isolation, little has been studied about how genetic
differences act together to alter an individual’s risk of paracet-
amol toxicity [16].
Uridine 5′-diphospho-glucuronosyltransferase
and Gilbert’s syndrome
Uridine 5′-diphospho-glucuronosyltransferase (UGT) cataly-
ses the major metabolic pathway of paracetamol by
glucuronidating its phenolic group to form APAP-glu, which
is excreted renally [28, 29]. There are at least 15 isoforms of
UGT in humans; UGT1A1, UGT1A9, UGT1A6 and
UGTB15 are reported to glucuronidate paracetamol.
Polymorphisms of these genes or associated regulatory se-
quences, or copy number variations (CNV) may contribute
to a reduction in UGT activity or indeed loss of function
and, therefore, reduce paracetamol glucuronidation.
Theoretically, this could result in increased fractional oxida-
tion and an increased propensity to toxicity (see Fig. 2 for the
metabolic pathways affected by UGT) [17, 30, 31].
Conversely, the UGT1A rs8330 polymorphism has been as-
sociated with increased levels of paracetamol glucuronidation.
A study in human liver tissue samples found that UGT1A
rs8330 G polymorphism was consistently associated with
higher rates of paracetamol glucuronidation. The same poly-
morphism was subsequently demonstrated to have a signifi-
cantly lower incidence in patients who developed
hepatotoxicity from unintentional paracetamol overdose when
compared to liver failure from other causes [32]. This suggests
that the higher rates of glucuronidation associated with this
UGT1 polymorphism protect against paracetamol hepatotox-
icity by decreasing the fractional proportion of paracetamol
available for oxidation.
Gilbert’s syndrome
There is heterogeneously reduced UGT activity in patients
with Gilbert’s syndrome (present in 5–7% of the population,
varies by ethnicity and by diagnostic method). The concern
surrounding Gilbert’s syndrome and paracetamol is based on
the putative theory that a reduction in the glucuronidation of
paracetamol leaves a greater fraction of the drug available to
be oxidised, potentially causing toxicity.
Although there are no case reports or case series suggesting
increased risk of paracetamol-related toxicity in people with
Gilbert’s syndrome, a number of controlled studies have in-
vestigated the effect of this reduction in UGTactivity on para-
cetamol metabolism. There are conflicting results possibly
due to differences in experimental design.
Three pharmacokinetic (PK) studies (total of 30 patients)
have suggested that those with Gilbert’s syndrome have lower
paracetamol glucuronidation [28, 33, 34]. One of these studies
demonstrated a 1.7-fold higher recovery of toxic metabolites
in those with Gilbert’s syndrome compared to controls [33],
although a larger study only found a higher rate of recovery of
toxic metabolites in those patients stratified by having the
lowest UGT activity [28]. A different PK investigation, com-
paring Gilbert’s patients and controls, demonstrated no differ-
ence between ratios of metabolites [29]. Thus, the findings of
these studies are inconsistent.
None of these investigations comprehensively assess the
effect of Gilbert’s syndrome on the full PK and metabolite
profiles of paracetamol. Furthermore, no studies exist investi-
gating whether there is an over-representation of patients with
Gilbert’s syndrome in those who develop toxicity following
paracetamol overdose. There is no good quality clinical evi-
dence to suggest that a diagnosis of Gilbert’s syndrome puts
patients at risk of toxicity at therapeutic doses of paracetamol,
and the assertion that patients are at greater risk of toxicity
following overdose remains theoretical (see Fig. 2 for the
pathways metabolic affected by UGT).
Sulphotransferase superfamily
Sulphotransferase (SULT) enzymes catalyse the addition
of a sulphate to the phenolic group of paracetamol to form
APAP-sul (30–44% of total dose at therapeutic doses) [13,
17]. SULT1A1 is believed to be the major enzyme asso-
ciated with paracetamol sulphation, although SULT1A3/4
Eur J Clin Pharmacol
and SULT1E1 have also been implicated in the foetus and
neonates [20, 35, 36].
In theory, reduced paracetamol sulphation due to reduced
sulphotransferase activity could lead to increased paracetamol
oxidation to NAPQI. No PK studies investigating paracetamol
metabolism in humans with SULT polymorphisms or CNVs
have been conducted. Moreover, no studies have been under-
taken in controlled circumstances to demonstrate whether a
reduction in sulphotransferase activity causes increased para-
cetamol oxidation or increased propensity to paracetamol tox-
icity at either therapeutic or supra-therapeutic doses. There is
no good quality clinical evidence to suggest that a reduction in
sulphotransferase activity affects paracetamol metabolism or
increases the risk of paracetamol toxicity (see Table 1 in the
supplementary data for a summary of the evidence and see
Fig. 2 for the metabolic pathways affected by SULT).
Cytochrome P450
CYP2E1 is likely to be the most important enzyme involved
in the bioactivation of paracetamol to NAPQI [20]. The cod-
ing portion of the gene is well conserved across species, al-
though polymorphisms have been described in the non-coding
portions of the gene [37]. There are significant inter-ethnic
differences in the polymorphism frequency, but it is unclear
whether these result in a clinically relevant phenotype (see
Table 2 in the supplementary data for a summary of the
evidence) [37]. It is widely accepted that alcohol use and a
number of pharmacological agents, for example isoniazid,
induce expression of CYP2E1 (see section BPotential drug
interactions with paracetamol metabolism^ and section
BAlcohol use^).
CYP2D6 is a minor enzyme associated with the oxidation
of paracetamol; however, it constitutes the most variable of the
CYP450 genes as well as the most complex CYP450 locus
[38]. As with CYP2E1, there are substantial inter-ethnic dif-
ferences in CYP2D6 across populations, ranging from com-
plete loss of function or reduction in functional activity (25–
70% of the population, dependent on ethnic origin and geo-
graphical location) to extensive, ultra-rapid metabolisers (1.5–
9.3% of the population) (see Table 3 in the supplementary data
for a summary of the evidence) [17, 38].
DNA samples obtained from patients enrolled by the Acute
Liver Failure Study Group suggest the rs776746 polymor-
phism in CYP3A5 is associated with increased bioactivation
of paracetamol via increased enzyme activity. This polymor-
phism was retrospectively found to be over-represented in
patients developing hepatotoxicity following intentional para-
cetamol overdose [39]. Although not traditionally believed to
be a CYP450 enzyme involved in paracetamol oxidation, it
may be that possession of this allele allows CYP3A5 to use
paracetamol as a substrate and hence enhance its bioactivation
with resultant liver injury.
No prospective studies have been conducted in humans
in controlled circumstances to demonstrate whether
CYP450 polymorphisms lead to an increase or a decrease
in paracetamol oxidation nor have there been studies dem-
onstrating that CYP450 polymorphisms in humans
Fig. 2 Genetic differences and paracetamol metabolism
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increase or decrease the risk of paracetamol toxicity be-
fore or after an overdose. There is no good quality clinical
evidence to suggest that CYP450 polymorphisms influ-
ence paracetamol toxicity (see Fig. 2 for the metabolic
pathways affected by CYP450).
Glutathione s-transferase
When formed by oxidation of paracetamol, NAPQI is rapidly
detoxified by conjugation with reduced GSH via reaction with
GSH’s sulfhydryl group. This reaction occurs both spontane-
ously (non-enzymatically) and enzymatically, mediated by
glutathione s-transferase (GST) [40]. GST is polymorphic
and three polymorphisms decrease or abolish GST activity,
although it is unclear whether possession of these polymor-
phisms leads to an increased propensity for paracetamol tox-
icity [41]. There is wide inter-ethnic variation in the frequency
of GST polymorphisms [17]. There is no good quality clinical
evidence from controlled studies in humans to suggest that
GST polymorphisms affect paracetamol toxicity either at ther-
apeutic or supra-therapeutic doses (see Table 4 in the
supplementary data for a summary of the evidence).
CD44
Two human genetic studies have suggested that polymor-
phisms in the CD44 gene may account for variations in tox-
icity following paracetamol overdose [39, 42]. CD44 is
expressed on leukocytes and has a role in mediating the innate
immune response. In one study, the CD44 rs1467558 poly-
morphism was reported to be significantly associated with an
ALT rise in independent cohorts of patients given a therapeu-
tic dose of 4 g/day of paracetamol over 7 days [42]. In silico
modelling suggests that rs146558 is a nonsynonymous single
nucleotide polymorphism that leads to disruption in protein
function. Furthermore, the same polymorphism was found to
be over-represented in patients developing acute liver injury
following high doses of paracetamol taken unintentionally
over several days [39]. Although CD44 is not involved in
paracetamol pharmacokinetics, it is implicated in the inflam-
matory response to liver injury [43].
Inter-individual variability and ethnicity
A number of studies have investigated the inter-individual
variation of paracetamol metabolism secondary to ethnic-
ity. Most of these studies are relatively small. The results
of these studies are mixed, and due to study design, it is
difficult to draw comparisons or firm conclusions (see
Table 5 in the supplementary data for a summary of the
evidence).
Although there may be differences in the metabolism of
paracetamol between people of different ethnicity, it is unclear
whether these are of any toxicological significance. There is
no good-quality evidence to suggest that people of different
ethnic backgrounds are of greater risk of toxicity at either
therapeutic or supra-therapeutic doses.
Age
Young age
A number of studies have investigated the difference in para-
cetamol metabolism between neonates, children and adults
and whether this affects their propensity to paracetamol-
induced toxicity.
Five PK studies all reported that children under 12 years of
age metabolise paracetamol predominately by sulphation
compared with adults (n = 114 children in total) and that the
adult pattern of metabolism is present beyond the age of 12
[44–48]. These findings are supported by a critical review of
the literature [49]. Three of the studies did not detect the prod-
ucts of oxidative metabolism following therapeutic dosing in
children [44, 46, 48]; adults have measurable products of ox-
idative metabolism following therapeutic dosing. One study
found that paracetamol t1/2 was prolonged in very early pre-
terms (28–32weeks’ gestational age), suggesting that the dose
interval may need to be extended in this group, although only
a single dose was given [47]. Another study reported that, in
children with fever, the area under the serum concentration-
time curve (AUC) increased by 13–44% from first dose to
steady state implying that paracetamol may accumulate in this
patient group although no ‘hepatotoxicity’ was demonstrated
[48]. A critical review of the literature suggested that paracet-
amol clearance is lower in neonates but that neonates and
children are capable of NAPQI formation, particularly follow-
ing multiple sequential overdoses, and that toxicity can occur;
they conclude that the differences in metabolism are due to
immature glucuronidation and that sulphation is the major
route of excretion [49].
Two case reports suggest that neonates and children
have a reduced propensity to toxicity following paraceta-
mol overdose due to differences in metabolism [50, 51].
One case report states that the recovery of the products of
oxidative metabolism in a child was 12% following over-
dose compared to an expected rate of 35–43% reported in
adults; although this patient developed hepatotoxicity and
was treated with NAC and dialysis, it was suggested that
this case was less clinically severe than would be expect-
ed in an adult [51]. Retrospective case series of paediatric
patients referred to national poisons centres also report a
lower rate of liver injury and hepatotoxicity in children
compared with adults following single acute overdose
[52–55]. However, further retrospective case series have
identified liver injury and hepatotoxicity in children fol-
lowing paracetamol intoxication, particularly following
Eur J Clin Pharmacol
multiple sequential overdoses, and that the mortality in
these cases can be high. Factors reported as increasing
the risk of liver injury and hepatotoxicity includes delayed
referral and/or management and concomitant ingestion of
other hepatotoxic agents [56, 57].
Evidence from metabolism studies, case reports and larger
systematic retrospective case reviews but no prospective con-
trolled trials demonstrate that following single acute paracet-
amol overdose, children may be relatively protected from
acute liver injury and hepatotoxicity when compared to adults
[15, 46, 51–53, 58]. However, following multiple overdoses
which is the predominant mode of paediatric overdose has
been reported [15, 51, 56–58]. Factors conferring relative pro-
tection to children from the toxic effect of paracetamol over-
dose include increases in paracetamol sulphation capacity
[44–48], relative immaturity of the CYP450 oxidation system
[15, 46, 49, 51] and the larger relative liver volume found in
children [59] but these theoretical mechanisms have not been
confirmed.
Older people
A number of investigators have looked into the effect of ad-
vancing age on the metabolism of paracetamol and whether
this increases the likelihood of paracetamol-induced toxicity.
Two large population-based studies reported that the rate of
paracetamol poisoning decreased with age from a peak in
adolescence and early adulthood [60, 61].
The data related to paracetamol metabolism and age are
inconsistent despite there being a number of investigations
published (> 150 subjects) [61–72]. Some PK studies report
an increased theoretical risk of toxicity with advancing age
[62–67] due to prolongation of t1/2 [62, 63], reduced paracet-
amol clearance [64, 67], increased paracetamol oxidation
caused by a reduction in glucuronidation and sulphation ca-
pacity [65] or a reduction in liver volume [66]. Conversely,
other PK studies imply that increasing age has no effect on
toxicity [68–72]. These studies report that paracetamol t1/2
[68, 69, 71], AUC and oral clearance [71] are unrelated to
age, that the rate of recovery of the products of paracetamol
oxidative metabolism is not affected in older subjects [69],
that the rate of conjugation is also not affected by increasing
age [69, 70] and that a higher Cmax in older people does not
translate into changes in ALT [72]. A retrospective case series
reported that, although the frequency of paracetamol poison-
ing is lower in older subjects, when paracetamol intoxication
does occur, it is more frequently associated with fulminant
hepatic failure and death and age is considered an independent
risk factor of morbidity and mortality in these cases [61].
These studies demonstrate inconsistent findings and this
inconsistency probably represents the heterogeneity of older
people in terms of co-morbidities, liver volume, organ dys-
function and concurrent medications. Differences in
experimental design are also likely to contribute to differences
in results. It remains unclear whether any changes in PK trans-
late to an increased propensity to toxicity with no studies
demonstrating this conclusively. Clinical experience suggests
that many older people do take regular paracetamol without
development of toxicity. There is a lack of good quality clin-
ical evidence that older people have a clinically significant
difference in paracetamol metabolism or are at increased risk
of toxicity at either therapeutic or supra-therapeutic doses.
Nutritional state and body weight
It has been suggested that acute and chronic malnutrition may
give rise to an increased propensity to paracetamol toxicity,
especially if multiple concurrent doses are taken [73, 74].
Malnutrition was an indication for using the high-risk treat-
ment line when two treatment lines were used to determine
need for NAC treatment in the UK [75]. It was believed that a
malnourished state depleted hepatic GSH and thus reduced the
ability to detoxify NAPQI leading to increased risk of toxicity
[73, 76]. Moreover, it has been suggested that starvation re-
duces liver glycogen storage and hence reduces UGT
conjugative ability leading to a greater fraction of the dose
being oxidised to NAPQI [77]. These conclusions came from
the observation of unexpected liver injury/hepatotoxicity, of-
ten as case reports, in patients clinically assessed as being
‘malnourished’ [73, 78–81]. However, malnutrition and star-
vation are difficult to assess clinically and in particular
protein-calorie malnutrition can co-exist with chronic alcohol
use and with inter-current acute or chronic illness, which may
independently or in concert increase the risk of paracetamol
toxicity and confound the assertion that malnutrition per se
increases the risk of paracetamol toxicity [6, 16, 73, 78–83].
The observation that causality has not been proven has led
some authors to cast doubt about the role of malnutrition as a
risk factor for paracetamol toxicity; indeed there is no con-
vincing evidence that malnutrition does increase the risk. (see
Table 6 in the supplementary data for a summary of the
evidence) [6, 16, 82–84].
In protein-calorie malnutrition, both GSH and CYP2E1
quantities would be reduced (as detailed by a reduction in both
GSH and CYP2E1 messenger RNA) and thus there would be
no net overall effect on toxicity [16, 85]. A different paper
suggests that there is no evidence that reduced food intake
over the course of a few days reduces liver glutathione [82].
CYP2E1 in addition to metabolising paracetamol also
metabolises acetone to glucose; it has been proposed that star-
vation increases ketone body formation and that these would
compete with paracetamol for CYP2E1 and may potentially
‘reduce toxicity’ [82].
In the UK, the licenced oral paracetamol dose in adults
is 4 g/day in 1 g doses every 4–6 h [86]. The same dose is
recommended in the USA and in Australia, except that in
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the USA, the oral dose has been reduced to 350 mg per
dosage unit in prescribed preparations [87, 88]. For sim-
plicity, the recommended oral dose for children in the UK
is in age bands; alternatively, 15 mg/kg is also recom-
mended [86]. The UK regulator recommends that in
adults weighing less than 50 kg, ‘clinical judgement’
should be employed when prescribing oral paracetamol
as these patients may be at increased ‘risk of hepatotox-
icity’ but does not specify a dose reduction. No recom-
mendation for an oral dose reduction due to low body
weight in the USA or Australia could be found. By con-
trast, for the intravenous (IV) preparation, the UK licence
recommends a dose of 4 g/day every 4–6 h for adults
weighing above 50 kg with a dose reduction to 3 g/day
in those who have ‘risk of hepatotoxicity’. For adults
weighing below 50 kg, the dose of IV paracetamol is
recommended at 15 mg/kg every 4–6 h with a maximum
dose of 60 mg/kg/day. The IV guidance is similar to that
recommended in the USA and Australia.
There are multiple reports detailing cases of iatrogenic
overdose of IV paracetamol in both children and adults. An
iatrogenic IV overdose of paracetamol was the subject of a
Scottish fatal accident inquiry [89, 90]. These case reports
generally involve the overdose of subjects weighing less than
50 kg and the majority of these case reports concern dose
miscalculation in paediatrics. Case reports exist of under-
weight individuals (< 50 kg) developing liver injury or hepa-
totoxicity when given ‘therapeutic doses’ of oral paracetamol
[91, 92]. In these cases, individuals were given 133, 91 and
88 mg/kg/day orally over a number of days. While the doses
were within the recommended range for oral administration,
each patient was given more than the 60 mg/kg/day of para-
cetamol recommended for IVuse but less than the 150-mg/kg/
day limit recommended for immediate treatment of therapeu-
tic excess. Interestingly, a multi-centre, randomised, double-
blind, active controlled, parallel group trial of long-term para-
cetamol with naproxen as a comparator group for pain related
to osteoarthritis over a 6–12-month period included patients in
the weight range of 41–190 kg, with the lowest weight patient
receiving 95.2 mg/kg/day [93]. Over the study period, there
were no reports of hepatic dysfunction or failure.
Notwithstanding, the appropriate oral paracetamol dose in
adults weighing less than 50 kg has not been investigated with
liver injury or hepatotoxicity as a primary endpoint. In a re-
view article describing toxicity from therapeutic doses of para-
cetamol, the weight of the patients was not considered in re-
lation to development of toxicity and it would be informative
to establish if the reports included in the review represented
patients with a weight less than 50 kg and what the milligram/
kilogram dose was [7].
Although there is no good-quality evidence to suggest
that the dose of oral paracetamol should be reduced for
individuals weighing less than 50 kg, it seems illogical
that the oral recommendations differ from those for intra-
venous administration or the oral milligram/kilogram dose
recommended for children. Indeed, some UK National
Health Service organisations have independently imple-
mented guidance suggesting that a lower dose of oral
paracetamol should be prescribed in those weighing under
50 kg but this represents organisational cautiousness [94].
It is difficult to assess the contribution of weight and nutri-
tion to paracetamol toxicity due to lack of good quality clinical
evidence.
Alcohol use
Case reports and retrospective case series have suggested that
chronic alcohol consumption increases the risk of toxicity
from paracetamol, perhaps even with therapeutic drug doses
[95–108]. A number of case reports describe patients devel-
oping acute liver injury and hepatotoxicity from a therapeutic
dose and conclude that patients with chronic alcohol use are at
heightened risk of paracetamol toxicity [95, 96, 106, 108,
109]. However, during alcohol consumption, the sensorium
may be clouded making the reliability of the dose history
uncertain. Due to concerns around increased vulnerability to
paracetamol toxicity, chronic alcohol consumption was a rea-
son to use the high-risk treatment link for consideration of
NAC treatment when risk stratification was recommended
[75].
It has been suggested that chronic alcohol abuse increases
susceptibility to paracetamol toxicity due to CYP2E1 induc-
tion [95, 96, 98–101], that hepatic GSH is reduced leading to
reduced NAPQI detoxification [95, 96, 98–101, 103, 104,
106, 109] and/or that glucuronidation is reduced leading to
increased fractional oxidation [95–97]. Other theories ad-
vanced for the observation of increased toxicity in chronic
alcohol consumers include disturbances to hepatocyte mem-
branes rendering them more vulnerable to insult, decreased
biliary excretion of paracetamol or reduced clearance [97].
In a controlled study investigating the effect of ethanol infu-
sion on paracetamol metabolism, subjects exposed to ethanol
were found to have an increase in the recovery of the oxidative
products of paracetamol metabolism compared to controls but
only by a small percentage (22%), and increased oxidation
was detected 8 h after the ethanol infusion had ceased [110].
By contrast, acute alcohol co-ingestion with paracetamol may
reduce the risk of toxicity because alcohol competes for
CYP2E1 and prevents paracetamol metabolic activation [16,
20, 102, 109, 111–117]. However, prospective studies done in
controlled circumstances or systematic reviews have found no
association with chronic alcohol use and increased suscepti-
bility to paracetamol toxicity at therapeutic doses [16, 84, 100,
113, 116–118].
Some authors have suggested that, once established, para-
cetamol toxicity may be more severe in those with chronic
Eur J Clin Pharmacol
alcohol consumption [119] although this is not a universal
finding [118]. This may be because chronic alcohol abusers
often present late with therapeutic misadventure, when toxic-
ity is established [83, 95–99].
There is no good quality clinical evidence from prospective
trials that alcohol consumption increases the risk of paraceta-
mol toxicity (see Table 6 in the supplementary data for a
summary of the evidence and Fig. 3 for alcohol’s effects on
paracetamol metabolism).
Potential drug interactions with paracetamol metabolism
Many case reports state that certain pharmacological agents
affect the metabolism of paracetamol, especially in relation to
rendering patients more susceptible to toxicity. Putative mech-
anisms include enzyme induction (increased paracetamol ox-
idation), enzyme inhibition (reduced conjugation) and gluta-
thione depletion (reduced NAPQI detoxification) (see Fig. 4
for potential sites of drug interactions with paracetamol me-
tabolism). However, aside from case reports, there is very little
evidence that drug interactions increase the risk of liver injury.
Enzyme induction
It has been proposed that pharmacological agents that induce
the CYP450 enzymes responsible for paracetamol oxidation
could theoretically increase the fraction of paracetamol
oxidised to NAPQI. A literature review concludes that thera-
peutic doses of paracetamol with or without CYP450 enzyme
inducers do not lead to an increased propensity to toxicity
[82]. See Tables 8, 9, 10, 11, 12, and 13 in the supplementary
data for a summary of the evidence relating to paracetamol
hepatotoxicity and exposure to CYP450 enzyme inducers.
Enzyme inhibition
It is postulated that drugs that inhibit glucuronidation may
increase the fractional proportion of paracetamol shunted to
oxidation. There is no good evidence that co-administration of
drugs that inhibit glucuronidation increases an individual’s
risk of paracetamol toxicity. See Tables 14, 15, 16, 17, 18 in
the supplementary data for a summary of the evidence relating
the enzyme-inhibiting drugs and paracetamol toxicity.
Reduced levels of glutathione
GSH binds NAPQI, thereby detoxifying it [120]. Disease
states may reduce the level of hepatic glutathione. A recent
literature review suggests that there is no convincing evidence
that these increase the risk of paracetamol toxicity at therapeu-
tic doses [84].
Paracetamol and chronic liver disease
Due to its ability to cause liver toxicity in supra-therapeutic
doses, there is theoretical concern about the administration of
paracetamol to patients with chronic liver disease (CLD).
Studies have demonstrated that there is not an increase in
CYP450 activity in CLD but rather that the enzyme activity
remains unchanged or decreases [121, 122]. Moreover, al-
though there is variation in CYP450 activity among both
healthy and diseased livers, cirrhosis was associated with a
significant decrease in CYP2E1 activity [123].
Investigation into the concentration of hepatic and plasma
GSH in liver disease has been mixed, with some reporting a
decrease in glutathione [124, 125] and others reporting an
increase [126, 127]. Even if GSH levels are decreased in
CLD, they would not be decreased to such an extent as to
cause toxicity at therapeutic doses as the studies have demon-
strated that chronically diseased livers remain capable of pro-
ducing GSH [76, 120].
The t1/2 of paracetamol is known to be increased in patients
with toxicity secondary to paracetamol overdose [128, 129],
viral hepatitis [130] and in patients with CLD [131–136].
However, in stable chronic liver disease, there is no accumu-
lation of paracetamol [134] and the excretion of toxic metab-
olites remained the same between those with mild or severe
liver disease and controls [131].
The UK regulator does not recommend a dose reduction in
hepatic disease but suggests avoiding large doses [86]. On the
basis of records in the US Federal Drug Administration’s
Adverse Events Reporting System and the Multiple Causes
of Death Files, which may signal a disproportionate preva-
lence of patients with pre-existing liver disease developing
liver injury when using paracetamol, but not on the basis of
conclusive evidence, the US currently requires paracetamol-
containing products to be labelled ‘ask a doctor before using
[paracetamol] if you have liver disease’, but stops short of
recommending a dose alteration [137]. It is likely that the
therapeutic doses of paracetamol are safe to use in both adults
and children with CLD; no studies have been conducted into
the administration of paracetamol during acute liver disease.
Conclusions
Given that paracetamol is one of the most widely consumed
medications globally, it is perhaps surprising that there are few
quality data that inform whether certain individuals have a
greater propensity to develop liver injury than others.
Although observational data suggest that non-overdose para-
cetamol ingestion may cause liver failure in a very small pro-
portion of people and ALT rises of uncertain clinical signifi-
cance occur in some patients treated with paracetamol in
RCTs, there is no good evidence that therapeutic doses of
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paracetamol present a greater risk of toxicity in any group
covered by this review [24–26].
A key question is does this lack of robust data matter?
Given its widespread use, any small increase in risk of toxicity
could translate into vulnerable individuals being harmed. As
the efficacy of paracetamol has been questioned in the setting
of chronic pain, it is important to understand safety/toxicity, in
order to protect users from unacceptable harms.
In our view, there are two particular scenarios that warrant
further discussion and research. The first setting is a speculative
future challenge. It is becoming increasingly cheap and straight-
forward to generate genetic information on people, including
Fig. 4 Potential sites of drug interactions with paracetamol metabolism
Fig. 3 Alcohol’s effect on paracetamol metabolism
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whole genome sequencing. In the near future, it is possible that
a patient’s genomic information will be available as a tool to
guide prescribing within the context of precision medicine. If,
or when, this situation is a reality, we may still not understand
whether the patient’s genome has a clinically important effect
on paracetamol metabolism and risk of toxicity. This highlights
an important disconnection between advancements in genomic
medicine and our understanding of the clinical phenotype in-
duced by gene changes with regard to both pharmacokinetics
and pharmacodynamics or the role of genetic variation in the
body’s response to liver injury when it does occur. However,
any future understanding of genomics altering paracetamol me-
tabolism and thus liver injury or altering the body’s response to
such an injury is unlikely to affect the vast majority of patients
who present following overdose, as pre-clinical data suggests
that everyone would develop liver injury given ‘sufficiently
high’ doses. In this future setting, there would be an argument
for robustly defining the risk of paracetamol with regard to
genetics and especially whether ‘sufficiently high’ dose to
cause liver injury in some patients falls within or just above
the therapeutic range. Failure to do this could lead to confusion
among patients and doctors, as genetic information will be
available without clarity about its impact on paracetamol pre-
scribing and overdose management.
At present, there is persisting confusion about whether the
oral dose of paracetamol should be reduced in adults with low
body weight. This has resulted in individual healthcare pro-
viders recommending dose reductions that are not reflected in
the drug licence. This leads to conflicting messages about
what constitutes an overdose. For example, a hospital may
recommend dose reduction in a patient weighing less than
50 kg but the same patient would take a higher dose paracet-
amol if they used the drug packaging for dosage information
in the community. We would suggest that research is needed
in this area to identify safety signals in low body weight, but
otherwise healthy, individuals. Such research could incorpo-
rate novel biomarkers of liver injury in mechanistic studies
and population level data linkage.
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